Protective vaccine against
View Patent ↗Vaccine formulations effective against Staphylococcus aureus , including methicillin-resistant Staphylococcus aureus (MRSA) are disclosed, as well as methods of using the vaccine formulations in the treatment, prevention and prophylaxis of Staphylococcus aureus infections in a subject.
1. A vaccine formulation comprising:
(a) four Staphylococcus aureus polypeptides, wherein the Staphylococcus aureus polypeptides are (i) glucosaminidase as set forth in SEQ ID NO:1, (ii) SA0688 as set forth in SEQ ID NO:2, (iii) SA0037 as set forth in SEQ ID NO:3, and (iv) SA0486 as set forth in SEQ ID NO:4, and
(b) a pharmaceutically acceptable carrier or diluent.
2. A method of inhibiting a Staphylococcus aureus infection in a subject, comprising administering a therapeutically effective amount of a vaccine formulation of claim 1 to a subject at risk of developing a Staphylococcus aureus infection, thereby inhibiting a Staphylococcus aureus infection in a subject.
3. The method of claim 2 , further comprising administering an antimicrobial agent to the subject, wherein the antimicrobial agent is administered before, concurrent with, or after the vaccine formulation.
4. The method of claim 3 , wherein the antimicrobial agent is selected from the group consisting of an aminoglycoside, a carbacephem, a carbapenem, a cephalosporin, a glycopeptide, a macrolide, a monobactam, a penicillin, a polypeptide, a quinolone, a sulfonamide, a tetracycline, chloramphenicol, clindamycin, lincomycin, fusidic acid, furazolidone, linezolid, metronidazole, mupirocin, nitrofurantoin, macrobid, platensimycin, quinupristin/dalfopristin, rifampin and rifampicin.
5. The method of claim 2 , wherein the Staphylococcus aureus infection is selected from the group consisting of a Staphylococcus aureus biofilm infection, a Staphylococcus aureus osteomyelitis infection and a biofilm-associated Staphylococcus aureus osteomyelitis infection.